These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1998997)

  • 21. Rapid measurement of blood leakage during regional chemotherapy.
    Alexander C; Omlor G; Berberich R; Gross G; Feifel G
    Eur J Nucl Med; 1993 Mar; 20(3):187-91. PubMed ID: 8385020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas].
    Tonak J; Hohenberger W; Göhl J
    Chirurg; 1984 Aug; 55(8):499-504. PubMed ID: 6488994
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cardiocirculatory side effects of hyperthermic extremity perfusion].
    Omlor G; Molter G; Meessen S; Gross G; Seyfert U; Feifel G
    Langenbecks Arch Chir; 1993; 378(1):17-20. PubMed ID: 8437497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
    Klaase JM; Kroon BB; Beijnen JH; van Slooten GW; van Dongen JA
    Br J Cancer; 1994 Jul; 70(1):151-3. PubMed ID: 8018528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study.
    Guadagni S; Santinami M; Patuzzo R; Pilati PL; Miotto D; Deraco M; Rossi CR; Fiorentini G; Di Filippo F; Valenti M; Amicucci G
    Melanoma Res; 2003 Feb; 13(1):51-8. PubMed ID: 12569285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities.
    Klaase JM; Kroon BB; van Geel BN; Eggermont AM; Franklin HR; Hart GA
    Am J Surg; 1994 Jun; 167(6):618-20. PubMed ID: 8209941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity.
    Byrne DS; McKay AJ; Blackie R; MacKie RM
    Eur J Cancer; 1996 Nov; 32A(12):2082-7. PubMed ID: 9014749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic leakage during isolated limb perfusion for melanoma.
    Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR
    Br J Surg; 1993 Sep; 80(9):1124-6. PubMed ID: 8402109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.
    Kam PC; Thompson JF
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1039-45. PubMed ID: 20604735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New modifications in isolated extremity perfusion ].
    Aigner K; Hild P; Hundeiker M
    Z Hautkr; 1982 Jul; 57(14):1044-54. PubMed ID: 6889794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
    Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity.
    Paulsen IF; Chakera AH; Schmidt G; Drejøe J; Klyver H; Oturai PS; Hesse B; Drzewiecki K; Mortensen J
    Clin Physiol Funct Imaging; 2015 Jul; 35(4):301-5. PubMed ID: 24902761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
    Papadia F; Basso V; Patuzzo R; Maurichi A; Di Florio A; Zardi L; Ventura E; González-Iglesias R; Lovato V; Giovannoni L; Tasciotti A; Neri D; Santinami M; Menssen HD; De Cian F
    J Surg Oncol; 2013 Feb; 107(2):173-9. PubMed ID: 22674435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
    Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
    J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperthermic isolation-perfusion with melphalan, a preliminary appraisal of local and general effects in malignant melanoma.
    Lejeune FJ; Mathieu M; Kenis Y
    Tumori; 1977; 63(3):289-98. PubMed ID: 898296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
    Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
    Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma.
    Vrouenraets BC; Kroon BB; Klaase JM; Nieweg OE; van Slooten GW; van Dongen JA
    Melanoma Res; 1995 Dec; 5(6):425-31. PubMed ID: 8589617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.